Search
Displaying all 2 results
Adagrasib
go.drugbank.com/drugs/DB15568
ApprovedInvestigational
Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosph...
Batoprotafib
go.drugbank.com/drugs/DB19137InvestigationalBatoprotafib is under investigation in clinical trial NCT04330664 (Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)).